Novel Drugs and Smart Devices for Respiratory Disorders, 2030 - Focus on Asthma, COPD and Cystic Fibrosis

World News: . []

Dublin, Aug. 10, 2018 (GLOBE NEWSWIRE) -- The report has been added to offering. The Novel Drugs and Smart Devices for Respiratory Disorders, 2018-2030' report provides a comprehensive study on the current landscape of novel therapies and smart devices being evaluated for the treatment of asthma, COPD and cystic fibrosis. The field has captured the interest of several drug developers, both small and large companies. With several novel drug candidates in development, we anticipate the market to witness continued growth over the next 5-10 years.

According to the Forum of International Respiratory Societies, around 4 million individuals die each year due to chronic respiratory diseases. The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. Specifically, COPD is currently known to be the fourth leading cause of death worldwide. According to the data provided by the WHO, more than 3 million people die annually from COPD; this represents a total of 6% of the global annual deaths. Around 90% of these deaths occur in low and middle-income countries. Asthma, on the other hand, is more common in pediatric population. Asthma alone results in more than 30% of pediatric hospitalizations. Moreover, it is responsible for around 180,000 annual deaths worldwide.In addition to asthma and COPD, other chronic respiratory disorders are also associated with high unmet needs. Specifically, the patients suffering from cystic fibrosis, which is known to have a global prevalence of 70,000, have reported median lifespan of less than 30 years. In addition, the patients suffering from cystic fibrosis are at a relatively higher risk of acquiring life threatening lung infections. The high prevalence, high rate of hospitalization and high cost of treatment for these disorders places a huge burden on the society in terms of direct healthcare costs and the loss of productivity associated with disability and premature mortality of the patients.Although these diseases cannot be cured, government agencies and big pharma companies have made significant investments in R&D to improve disease management and address the unmet needs. These investments and development initiatives have led to the approval of several therapies, such as LAMA / LABA fixed dose combinations, ICS / LAMA / LABA fixed combinations, CFTR modulators, and novel biologics and antibiotics, which have helped improve the quality of life of patients. The industry is gradually transitioning towards the development of more targeted therapies. This shift is facilitating a scenario, wherein therapeutic strategies are changing from broad spectrum remedies to those that target individual patient segments.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The research, analysis and insights presented in this report include potential sales of novel therapies, as well as smart inhalers that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

For more information about this report visit


CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Devices

More news and information about Research and Markets

Published By:

Globe Newswire: 15:15 GMT Friday 10th August 2018

Published: .

Search for other references to "novel" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us